登录 | 注册    关注公众号  
微信公众号
搜索

KIR2DL1信息

英文名称:Killer cell immunoglobulin-like receptor 2DL1
中文名称:杀伤细胞免疫球蛋白样受体2DL1
靶点别称:KIR2DL1,NKAT-1,NKAT1,MHC class I NK cell receptor,Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 1,Killer Cell Immunoglobulin-Like Receptor, Two Domains, Long Cytoplasmic Tail, 1,P58 Natural Killer Cell Receptor Clones CL-42/47.11,Natural Killer-Associated Transcript 1,P58.1 MHC Class-I-Specific NK Receptor,CD158 Antigen-Like Family Member A,P58 NK Receptor CL-42/47.11,CD158A,Killer Cell Immunoglobulin-Like Receptor 2DL1,P58 Killer Cell Inhibitory Receptor KIR
上市药物数量:0
临床药物数量:1
最高研发阶段:临床二期

KIR2DL1产品列表

产品库
物种
标签
属性
货号 物种 产品描述 蛋白结构 纯度 活性
KI1-H5255
Human
Human KIR2DL1 / CD158a / NKAT-1 Protein, Fc Tag
 
评论(0)
 

KIR2DL1 分子别名

CD158a

KIR2DL1 分子背景

Killer cell immunoglobulin-like receptor 2DL1(KIR2DL1), which belongs to the immunoglobulin superfamily, is an inhibitory receptor of NK cells. Regulation of NK cell activity is mediated through killer-cell immunoglobulin-like receptors (KIR) ability to recognize human leukocyte antigen (HLA) class I molecules as ligands. Interaction of KIR and HLA is implicated in viral infections, autoimmunity, and reproduction and there is growing evidence of the coevolution of these two independently segregating gene families. Association of KIR2DL1 with β-arrestin 2 mediated recruitment of the tyrosine phosphatases SHP-1 and SHP-2 to KIR2DL1 and facilitated downstream inhibitory signaling.

KIR2DL1 前沿进展

KIR2DL1临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Lirilumab IPH-21; NN-1975; IPH-2101; IPH-2102; BMS-986015 临床二期 诺和诺德制药 实体瘤, 白血病, 头颈部鳞状细胞癌, 淋巴细胞性白血病, 阴燃多发性骨髓瘤, 霍奇金病, 肿瘤, 多发性骨髓瘤, 膀胱癌, 急性髓细胞样白血病, 非霍奇金淋巴瘤, 慢性淋巴细胞白血病 详情

消息提示

请输入您的联系方式,再点击提交!

确定